The objective of this trial is to guarantee a follow-up of all stroke and transient ischemic attack (TIA) patients. With this follow-up assessment long term effects of therapy and prevention measures can be detected and monitored. It is part of quality assurance.
Primary efficacy endpoint: Number of patients who state that they received all the information they want about the causes and nature of their illness Key secondary endpoint(s): Compliance/adherence with discharge medication. Re-events. Degree of Disability. Activities of daily living. Mortality.
- Observation: Cohort
- Perspective: Prospective
- Sampling: Non-Probability Sample
Stroke and TIA patients treated at the Charite with acute stroke or TIA onset less than 7 days
|Type||Measure||Time Frame||Safety Issue|
|Primary||Primary efficacy endpoint: Number of patients who state that they received all the information they want about the causes and nature of their illness.||September 2010||No|
|Secondary||Compliance/adherence with discharge medication Activities of daily living||September 2010||No|
|Secondary||Degree of Disability||September 2010||No|